Trial NCT04471519 ; CTRI/2020/07/026300
Publication Ella R, 2020
Primary outcome on the report: The primary outcome was neutralising antibody titres evaluated by wild-type virus neutralisation assays, namely, (i) a plaque-reduction neutralisation test (PRNT50) and (ii) a microneutralisation assay (MNT50)